Health Canada Approval of Phase 2 Clinical Trial with Low-Dose Psilocybin

TORONTO, Jan. 24, 2023. Diamond Therapeutics Inc. ( " Diamond " ), a drug development company focused on low-dose psychedelic-derived therapies for use in the treatment of mental health, is pleased to announce it has received Health Canada approval to...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials